For its fourth fiscal quarter (ending December 31), Bristol-Myers Squibb Co (NYSE: BMY) has reported a -95% decline in E.P.S. from $0.87 a year ago to $0.04 in the current quarter. E.P.S. were $-4.41 for the latest four quarters through December 31 versus $3.88 for the same period a year ago — a decline of -214%.
Recent Price Action
Bristol-Myers Squibb Co (NYSE: BMY) stock closed at $57.42 on 2/6/25 after a decline of -3.8%. Moreover, trading volume in this decline was exceptionally high at 234% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -2.8% during the last week.
Current PriceTarget Research Rating
Bristol-Myers Squibb has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Bristol-Myers Squibb has a neutral Appreciation Score of 54 but a good Power Rating of 85, resulting in the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment